Streetbeat News

Revenues

OM

Outset Medical forecasts its FY24 revenue to be in the range of $145M-$153M, which is around the analyst estimate of $148.841M.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:04 pm

PLYM

Plymouth Industrial REIT (PLYM) reported a Q4 AFFO of $0.48 per share, up 14.29% from $0.42 YoY. However, Q4 sales of $50.75M missed the $50.91M estimate, a 7.25% increase from last year's $47.32M.

Portfolio Pulse from Happy Mohamed

February 21, 2024 | 10:03 pm

DOCN

DigitalOcean projects its FY24 adjusted EPS to be between $1.60 and $1.67, compared to the estimated $1.62. The company also forecasts revenue to be in the range of $755 million to $775 million, versus the estimated $767.145 million.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:01 pm

AGR

Avangrid (NYSE:AGR) reported Q4 2023 adjusted EPS of $0.97, surpassing the $0.91 estimate. However, its sales of $2.28B fell short of the $2.40B estimate, marking a 5.75% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:00 pm

OLO

Olo, a software platform for restaurants, forecasts its FY24 revenue to be between $269.0M and $272.0M, surpassing the estimated $258.651M.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 9:57 pm

OLO

Olo, a software platform company, forecasts its Q1 2024 revenue to be between $64M and $64.5M, surpassing the estimated $60.671M.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 9:57 pm

BALY

Bally's Corporation projects its FY24 revenue to be between $2.5 billion and $2.7 billion, which is in line with the estimated $2.668 billion.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 9:55 pm

CLPT

ClearPoint Neuro, Inc. (NASDAQ:CLPT) announced FDA clearance and first-in-human cases for its ClearPoint 2.2 Software with integrated Maestro Brain Modeling. Additionally, a validation study for the ClearPoint Maestro Brain Model was published in NeuroImage. The ClearPoint system offers precise navigation for various brain procedures, with the Maestro Brain Model enhancing accuracy and reproducibility in segmentation of brain structures. The first clinical cases using ClearPoint 2.2 were successfully completed, with a full market release expected in the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 9:54 pm

NVDA

QQQ

SOXX

SPY

Nvidia Corp. (NASDAQ:NVDA) reported Q4 earnings with a revenue of $22.10 billion and EPS of $5.16, surpassing Street estimates. The company's revenue saw a 265% year-over-year increase, with significant growth in the Data Center and Gaming sectors. Nvidia's Q1 revenue guidance of $24.0 billion also exceeds expectations. Shares rose 6% in after-hours trading, with a 40.25% increase year-to-date, outperforming major ETFs like SPY, QQQ, and SOXX.

Portfolio Pulse from Chris Katje

February 21, 2024 | 9:54 pm

RUN

Sunrun, a leading residential solar energy company, has reaffirmed its financial guidance, projecting positive cash generation cumulatively from the fourth quarter of 2023 through the fourth quarter of 2024. Additionally, the company expects to achieve an annualized cash generation run-rate of between $200 million and $500 million in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 9:54 pm